07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Acton Pharmaceuticals, Meda deal

Meda completed its acquisition of Acton for $135 million in cash. Acton is also eligible for a near-term undisclosed development milestone of $10 million and sales-based milestones, which the company said may bring the total...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Acton Pharmaceuticals, Meda deal

Meda will acquire Acton for $135 million in cash plus a $10 million near-term undisclosed development milestone. Acton is also eligible for sales-based milestones, which the company said may bring the total deal value up...
07:00 , Sep 2, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allenex AB (SSE:ALNX) gained SEK1.03 (48%) to SEK3.19 on Thursday after saying Mexico approved XM-ONE to detect human leukocyte antigen (HLA) and non-HLA antibodies between donor and recipient in organ transplantations. XM-ONE is...
23:58 , Aug 30, 2013 |  BC Extra  |  Company News

Meda to acquire asthma play Acton

Meda AB (SSE:MEDA) will acquire asthma play Acton Pharmaceuticals Inc. (Marlborough, Mass.) for $135 million in cash plus a $10 million undisclosed near-term development milestone. Acton is also eligible for sales-based milestones that the company...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Aerospan flunisolide HFA regulatory update

FDA approved an sNDA from Acton for Aerospan flunisolide HFA as maintenance treatment of asthma in patients >=6 years of age. Acton plans to launch the hydrofluoroalkane (HFA)-propelled inhaled formulation of flunisolide in the U.S....
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Acton Pharmaceuticals, Sanofi sales and marketing update

Sanofi granted Acton exclusive development and commercialization rights to Nasacort HFA triamcinolone acetonide in the U.S. to treat nasal allergy symptoms. The once-daily product is an intranasal corticosteroid dry-aerosol formulation that contains hydrofluoroalkane (HFA). Sanofi...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Aerospan flunisolide HFA regulatory update

Acton submitted an sNDA to FDA for Aerospan flunisolide HFA to include manufacturing information and data to support a commercial launch. Acton said the PDUFA date is March 3, 2011, and anticipates a launch in...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Acton board of directors update

Acton Pharmaceuticals Inc. , Marlborough, Mass.   Business: Inflammation   Appointed: Scott Carter of Sequoia Capital  ...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Acton, Forest Laboratories sales and marketing update

Acton received exclusive, worldwide rights to develop and commercialize Forest's Aerospan flunisolide. Forest will receive an undisclosed upfront payment and is eligible for milestones and royalties. The hydrofluoroalkane (HFA) formulated inhaled corticosteroid was approved in...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Financial News

Acton Pharmaceuticals completes venture financing

Acton Pharmaceuticals Inc. , Marlborough, Mass.   Business: Inflammation   Date completed: 1/6/10   Type: Venture financing   Raised: $15 million   Investor: Sequoia Capital  ...